SUMMARY 94.4 (64.3-129.6) versus 64.6 (34.8-126.9) 
Pharmacokinetic interactions causing deviations in measured concentrations of opioids in the presence of propofol are known to occur. Gepts 1 observed a 20% increase in plasma alfentanil concentrations and Ben Shlomo et al 2 and Kazama et al 3 reported similar increases in plasma concentrations of fentanyl. Possible mechanisms for this interaction include direct inhibition of cytochrome P450 enzymes by propofol 4 , propofol-induced decrease in hepatic blood flow 5 and competition for first pass pulmonary uptake 6 . Vuyk 7 suggested that propofol should also cause a reduction in the metabolism of both fentanyl and sufentanil, as these drugs have similar metabolic pathways to alfentanil.
Remifentanil is unique among the available opioids because of its rapid hydrolytic cleavage by nonspecific tissue and plasma esterases. The present study, therefore, was designed as a preliminary investigation to determine whether propofol altered remifentanil concentrations during co-infusion.
MATERIALS AND METHODS:
The study was approved by the Clinical Research and Ethics Committee of the Royal Melbourne Hospital Research Foundation. Written informed consent was obtained from patients undergoing noncardiovascular surgery. Lean body mass (LBM) was calculated using each patient's total body weight (TBW) in kg, height (Ht) in cm and sex from the formula of James 11 : LBM (males)=1.10 TBW-128 (TBW/Ht) 2 or LBM (females)=1.07 TBW-148 (TBW/Ht) 2 . Ideal body weight was determined from a height-for-weight chart 12 . Exclusion criteria were 1) cardiovascular disease; 2) pregnancy or lactation and 3) inability to provide informed consent.
The patients did not receive any premedication. A 16 gauge intravenous cannula was inserted into an antecubital vein and Hartmann's solution was administered at 10 ml.kg -1 .h -1 . Following infiltration of local anaesthetic, a 20 gauge radial arterial cannula was inserted for blood sampling and continuous blood pressure monitoring. A forced-air-warming blanket was placed over each patient and switched to the medium setting. Supplemental oxygen was administered via a facemask. Oxygen saturation, respiratory rate, heart rate (HR) and mean arterial blood pressure (MAP) were monitored continuously (AS/3, Datex, Helinski, Finland).
In the first stage, remifentanil was infused at a constant rate (250 ng.kgLBM -1 .min -1 ) for 30 min. Arterial blood samples (3 ml) were taken at 0, 1, 2, 3, 5, 7, 10, 15, 20, and 30 min. The samples were immediately placed in 5 ml screw-top vials containing 60 µl of 50% (w/v) citric acid and mixed by inversion and then held in crushed ice. An additional 2 ml arterial blood sample was taken at 20 min for blood gas analysis. At least 15 min after completion of the first infusion, anaesthesia was induced with propofol (10 mg.ml -1 ) using a computer controlled syringe pump (Diprifusor™, Graseby, Bundall, Qld, Australia) set to a target blood concentration of 6 µg.ml -1 . After the patient lost consciousness, rocuronium (0.6 mg.kg -1 IV) was given. The trachea was then intubated and the patient's lungs were ventilated with 100% oxygen (9 breaths.min -1 ). Anaesthesia was then maintained by setting the Diprifusor™ to a target propofol blood concentration of 3 µg.ml -1 . Paralysis was maintained with intravenous bolus doses of rocuronium as required. A second constant-rate infusion of remifentanil (250 ng.kgLBM -1 .min -1 ) was commenced at least 40 min after induction of anaesthesia with propofol and maintained for 30 min. Blood samples were taken as for the first infusion. Additional blood samples were taken at 5 and 10 min before commencing the second remifentanil infusion. All remifentanil samples were frozen at -18°C and assayed within 72 hours of the collection time. Propofol samples were assayed within three days of collection.
Remifentanil was assayed using a gas chromatography technique 13 which was linear to >100 ng/ml, had a limit of detection of 0.2 ng/ml and a coefficient of variation of 4.4% at 5 ng/ml. Propofol concentrations were determined using a high performance liquid chromatography assay, modified from the method of Plummer 14 . This assay was linear to >20 µg.ml -1 , had a limit of detection of 0.025 µg.ml -1 and a coefficient of variation of 4.1% at 2 µg.ml -1 . The areas under the remifentanil concentrationtime curves (AUC) were manually calculated using multiple polygons. The remifentanil alone and remifentanil plus propofol AUC, and remifentanil concentrations at 30 min in the two groups, were compared using a paired signed rank test, as the data were not normally distributed. Two-way repeated measures ANOVA, adjusted for Greenhouse-Geisser values, was used to assess within patient changes in propofol concentration over time, between subject changes and parallelism. The relationship between target and measured propofol concentrations over time was tested with one-way repeated ANOVA. It was assumed data had equal variance. Sequential analysis 15 was used to determine the number of patients needed to reach an end-point for difference (P<0.05) or non-difference (P<0.14) in AUC for successive subjects as there was no relevant data available to perform a prospective power analysis. HR and MAP differences over time between the two groups were compared using repeated measures ANOVA, adjusted for Greenhouse-Geisser values. Two-tailed, paired t-tests were used to compare HR and MAP between the two groups at each time point with Bonferroni correction. Results are presented as mean ±standard deviation or median (range); P<0.05 was considered statistically significant.
RESULTS
Sequential analysis of data, testing for a significant difference of P<0.05, resulted in cessation of the study after the enrolment of eight patients. Infusion concentration/time profiles for remifentanil alone and for remifentanil in the presence of a propofol infusion are shown in Figure 1 . Table 1 provides demographic characteristics and individual remifentanil concentration-time AUCs of the patients studied. Results for propofol concentrations in one subject were not available. Propofol concentrations of 3.5 (2.6-4.5) µg.ml -1 during the 30-min infusion were relatively constant, but significantly exceeded the prediction of the Diprifusor™ of 3.0 µg.ml -1 (P=0.0001, n=7). Propofol concentrations did not change significantly over time (P>0.05, n=7).
The mean area under the remifentanil concentration/time curve obtained during propofol infusion of 94.4 (64.3-129.6) was significantly greater than the mean AUC of the remifentanil infusion alone-64.6 (34.8-126.9) ng.ml -1 .min -1 ; P=0.008, n=8 ( Figure  2 ). However, there was no significant difference between the mean concentrations of remifentanil at 30 min of 4.6 (3.2-5.7) versus 3.8 (1.6-4.9) ng.ml -1 ; P>0.05, n=8. The magnitude of effect in the individual eight patients was not consistent. Half of the patients showed less than a 10% increase in the AUC for the second remifentanil infusion in the presence of propofol, but in all patients the AUC was greater during the second infusion than during the first (See Figure 1) .
When remifentanil was infused alone, the mean HR increased by 15% over the 30 min period. When remifentanil was co-infused with propofol, there was a 19% decrease in HR over the same period. A significant difference in parallelism was detected between the two curves (P<0.0001, n=8). HR was significantly greater for the combined remifentanil and propofol infusion at time 0 and at 5 min when compared with remifentanil infusion alone (P<0.05, n=8). However by 30 min, HR for the combined infusion was significantly lower than the remifentanil infusion (P<0.05, n=8) (Figure 3) .
With remifentanil infused alone, MAP remained stable over the first 20 min, but decreased by 34% over the same period in the presence of propofol ( Figure 4) . A significant difference in parallelism was detected between the two curves (P<0.0001, n=8). MAP was not significantly different between the two groups at 0 min (P>0.05, n=8), however at 15 minutes and later, MAP for the combined infusion was significantly lower than for remifentanil infused alone (P<0.01, n=8). Due to the marked decrease in MAP over time in 7 of the 8 patients, lactated Ringer's solution was infused from 20 min onwards during the combined infusion. Oxygen saturation in all subjects was >96% throughout the study. Respiratory rates remained at control levels during the initial remifentanil infusion, and were controlled during the propofol anaesthesia with machine ventilation. No patient reported recall of events during the combined remifentanil-propofol infusion at a postoperative interview.
DISCUSSION
The concentration of remifentanil, infused in the presence of a constant concentration of propofol, was quite variable but on average 33.5% greater than control in the first 15 minutes of the remifentanil infusion. At 30 minutes, the remifentanil concentration was 22% higher in the presence of propofol; however, this difference was not statistically significant. An increased sample size may have revealed a significant difference, but the study was terminated when significance was reached for the primary outcome variable. We chose AUC as the primary outcome as it yielded a single measure with the ability to identify a systematic difference in concentration between the treatments, as a function of time. This approach avoided the problem of having to correct for multiple comparisons, which has the inherent penalty of a reduction in statistical power, which would have been the case if the remifentanil concentrations were simply compared at each time point. A particular advantage of sequential analysis in a pilot study of this type, which is not available in other tests, is the ability to detect non-difference, if it had occurred, and to terminate the study and avoid unnecessary experimentation 16 . The observed change in the infusion pharmacokinetics of remifentanil is likely to be due to the presence of propofol as patients acted as their own control. At least 40 minutes was allowed between remifentanil infusions. Practical considerations dictated that the remifentanil alone infusion preceded the remifentanil/propofol infusions. In view of the rapid biodegradation of remifentanil, the interval of 40 minutes, the undetectable remifentanil concentra- tions at the commencement of the second infusion and the fact that degradation occurs in all tissues, it is highly unlikely that remifentanil sequestered in tissues in any way influenced the second phase of the study. Also, remifentanil was infused according to lean body mass, which is associated with less intersubject variability 17, 18 . The remifentanil infusion rate chosen was sufficiently high for the purposes of the assay, but low enough to avoid pre-operative complications, such as respiratory depression. The muscle relaxant used, rocuronium, has been shown not to interact with propofol or opioids 19 . A further difference between the infusions is the presence of artificial ventilation in the second infusion which is a possible but, in our view, an unlikely cause of the result.
One possible explanation of our result is a change in the distribution of remifentanil due to the haemodynamic effects of propofol. It is well documented that propofol causes arterial hypotension 20, 21 which would be expected to lead to a reduction of circulating blood volume. This has been attributed to an increase in venous capacitance by relaxing venous smooth muscle tone 22 and a significant decrease in cardiac output 23 . Remifentanil and propofol are known to interact and cause cardiovascular depression and this was observed. But the increase in the remifentanil concentrations occurred well before the haemodynamic changes that were observed.
Our results are consistent with those of Matot et al 6 , who demonstrated that, in the case of alfentanil and fentanyl, first-pass pulmonary uptake is decreased due to competition with propofol. Duthie et al 10 reported that the lungs did not extract remifentanil, however their study was conducted in the presence of propofol. As with the other opioids it appears that remifentanil competes with propofol for hydrophobic binding in the lungs.
For the clinician, it is important to note that in the presence of propofol, remifentanil reaches much higher concentrations, in some but not all patients, in the first 15 minutes than when compared with remifentanil is infused alone. Variability in remifentanil concentrations achieved with a constant-rate infusion based on LBM was not unexpected, and considerable inter-individual pharmacokinetic variability with opioids has been reported in humans 7 . Because the effect does not seem predictable, it is doubtful that infusion regimens need to be altered to account for this interaction. A consequence could be unexpected early apnoea, making pre-oxygenation an important consideration in all patients. Of further clinical consequence is the powerful haemodynamic interaction between propofol and remifentanil, which was not apparent when either drug is infused alone. A decrease in MAP averaging 34% over the 30 minute infusion would prompt some physicians to reduce infusion rates, particularly of propofol. While a natural response, this would be expected increase the risk of awareness. A more appropriate reaction might be to administer intravenous fluids and possibly a vasopressor.
Propofol infused to a target blood concentration of 3 µg.ml -1 in an unselected group of adult patients resulted, on average, in a measured concentration 17% greater than the target. These results are similar to those reported by Smith et al 24 for the Diprifusor™. Swinhoe et al 25 found that the Diprifusor™ predicted concentrations well when the pump was not running, but underpredicted concentrations when the pump was turned on. The use of an elimination based pharmacokinetic model in the Diprifusor™ is a probable explanation of this phenomenon.
In conclusion, the presence of therapeutic levels of propofol in the body significantly increased the mean area under the reminfentanil concentration-time curve when compared with remifentanil infused alone. The combination of propofol and remifentanil resulted in clinically significant haemodynamic disturbances during the latter part of the infusion. The difference in remifentanil concentrations was greatest earlier in the infusion, suggesting competition between propofol and remifentanil for lung binding sites.
